United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News Polycythemia vera treatment : Protagonist Therapeutics’ PTG-300 gets FDA ODD Protagonist Therapeutics has bagged the orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for… bypharmanewsdailyJune 18, 2020
